Private Market Stock Spotlight – NEURALINK UPDATE

Happy Tuesday To G.L.A NATION,

 We are back at it again with my mission to keep my network “in the know” with what’s really going on with the stock market and it’s best Investments. As you know, Im no longer a broker, or an advisor. I am an agent of truth. Today we are looking back into one of my personal favorite longterm private market investments NEURALINK. In my days as a stock broker we did a lot of biotech investing which I grew to hate because with biotech anything can happen for any reason. Neuralink is a complete different story, IMHO NEURALINK looks like the biotech of all biotechs, and with Elon Musk running the show I’m more than excited. Remember, one of my favorite mantras “The Companies Solving The Largest Problems Will Produce The Highest Returns!”

So, Neuralink is no longer a science-fiction slide. It is a clinical-stage platform company moving from first-in-human proof into scale.The latest public update cycle — captured in a Neura Pod field report built around patient talks, the rebuilt Neuralink careers page, new patient video, and comments from company leadership — shows three things at once. First, the implant is already changing daily life for people with ALS and high cervical spinal cord injury. Second, the company is building the manufacturing, robotics, and machine-learning stack required to go from dozens of patients to hundreds and then thousands. Third, Neuralink’s long-term thesis is larger than assistive tech: it wants a high-bandwidth link between human intent and machine intelligence.

Patient evidence is the most important near-term signal. Brad, an ALS patient implanted in late 2024 uses the device to control a computer after losing walking, speech, eating, and independent breathing function. I have communicated with Brad several times on X.com, me with my keyboard while Brad used his Neuralink.

His wife, Tiffany, walked through the practical reality of the implant: a coin-sized device under the scalp, wireless charging with a puck placed over the site, and a visible quality-of-life gain that does not cure ALS but restores digital agency. Audrey Crews, identified as patient P9 and implanted in July 2025 after more than 20 years of paralysis from a C4/C5 spinal cord injury, is using thought-controlled cursor movement to write her name, draw, and produce digital art. She has turned that capability into Neura Art Studio. Those are not lab demos. They are hours-per-day use cases.The company is also advertising its real bottlenecks. The careers page emphasizes implant hardware (biocompatible enclosure, wireless battery, signal-processing chips, and ultra-fine threads), a custom surgical robot, and machine learning aimed at decoding intent in milliseconds.

Neuralink president DJ Seo has described a “neural foundation model”: transformer networks fine-tuned on neural data rather than text. Even at a scale of roughly 20 participants at the time of that commentary, the team said it was already seeing non-obvious patterns. That is the private-market story in one line: every additional implant is both a medical outcome and a training-data asset. The strategic overlay remains Elon Musk’s original framing. Neuralink was founded to keep humans in the loop as AI accelerates. The medical work — paralysis, speech, vision via Blindsight, and broader brain/spine conditions — is both the ethical on-ramp and the regulatory path. The end-state described in the update is raw brain signals mapped to desired outcomes, with fewer intermediate interfaces in between. For private-market investors, Neuralink is a high-conviction, high-duration asset: pre-revenue, capital intensive, regulator-bound, and potentially category-defining if safety, bandwidth, and surgical throughput all hold as volume rises.

Ten Most Important Points for Investors

1. This is now a multi-patient clinical platform, not a single-hero experiment.
   The update centers on real users with ALS and quadriplegia who control computers for hours. Subsequent public reporting has put worldwide implant counts in the low-to-mid 20s by early 2026 and higher by mid-year, with sites in the U.S., U.K., Canada, and additional international expansion. Scale is still early, but the “one patient” risk is receding.

2. Quality-of-life evidence is the near-term valuation support.
   Brad’s ALS case and Audrey’s art-from-thought case matter because they show daily utility: cursor control, communication, creative work, and caregiver-visible independence. Investors should track hours of use, reliability, and whether function holds for years — not just launch-day videos.

3. The product is a system, not a chip.
   Neuralink is selling a stack: implant, wireless power, Bluetooth software, decoding models, and a surgical robot. That vertical integration is the moat. It is also the cost center. A private-market buyer is underwriting hardware iteration, OR workflow, software, and clinical ops at the same time.

4. Surgical automation is the hidden scaling lever.
   The company is in the hybrid phase: neurosurgeon plus robot. The stated destination is a fully autonomous surgical robot so throughput is not capped by specialist hours. If that works, implant volume can jump. If it slips, Neuralink stays a boutique clinical program. This is one of the most important operational KPIs in the name.

5. Neural data is becoming an AI asset.
   Ceo’s comments on neural foundation models are not marketing fluff. A fleet of implants that records intent at millisecond latency could produce a dataset no software lab can copy. At ~20 patients the signal is already interesting; at hundreds it could become a durable advantage in brain-to-AI interfaces.

6. The medical “side quest” is the commercial path.
   Restoring computer control, speech, and eventually vision (Blindsight) is how Neuralink earns FDA/Health Canada/MHRA permission, hospital relationships, and reimbursement conversations. The consumer/augmentation vision is the optionality. The paralysis and sensory-restoration work is the business.

7. Hiring and site strategy reveal the next phase.
   Year-round hiring in Austin and Northern California, plus a careers page built around “hardest engineering problems on Earth,” points to a company staffing for manufacturing, robotics, materials science, and ML — not just research papers. Employee counts in public datasets cluster around the mid-400s to ~500. That is still small relative to the ambition, which means execution risk remains concentrated in a lean team.

8. Capital structure is rich, illiquid, and valuation-sensitive.
   The last widely reported primary round was a ~$650 million Series E around mid-2025 at roughly $9–9.6 billion. Secondary-market prints have since implied much higher figures, with a wide range depending on the venue. Treat last-round primary value as the anchor and secondary prints as sentiment, not a mark. There is still no meaningful product revenue.

9. Key risks are binary and not fully priced by hype.
   Watch thread reliability and retraction over time, infection/hemorrhage risk as volume rises, battery/charging durability, model generalization across patients, hospital adoption, and any serious device-related adverse event. The company has publicly emphasized a clean serious-event record so far. That record has to survive scale. Regulatory timelines for commercial Telepathy/Blindsight remain multi-year. In every ELON product/service/or company, safety is the first priority!

10. The bull case is platform monopoly in high-bandwidth human I/O.
    If Neuralink becomes the default interface for severe motor and sensory loss, then later for speech and vision, it can own the on-ramp to human-AI alignment Musk described from the start: intent in, capability out, with fewer lossy layers in the middle. That is why I believe Neuralink is a generational private asset rather than a standard biotech name.The bear case is equally simple: safety, throughput, or decoding plateaus before the company reaches economic scale.

Coach Kyle’s take:
Neuralink is one of the few private names where the patient videos, the robot, and the model strategy all point the same direction. That does not make the private units “cheap.” It makes the underwriting question clear: can they industrialize brain surgery and keep the signal clean as the patient count moves from dozens to thousands? If yes, this is infrastructure for the AI decade.If no, it stays a remarkable clinical prototype.

This newsletter is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Neuralink is a private company. Shares, if available, are illiquid, high risk, and may become worthless. Always complete independent due diligence.